Raymond is an Associate in the firm’s Litigation Practice. He represents companies in high stakes commercial litigation, government and internal investigations, and regulatory compliance matters. His practice spans a broad range of industries, including health care, life sciences, and technology. Raymond appears in federal and state courts and arbitration proceedings, advising clients from early stage risk assessment through trial.
Prior to joining Mintz, Raymond practiced both in house and at global law firms. In private practice, he represented clients across industries in complex individual and class action commercial litigation, as well as government investigations and enforcement matters.
In house, Raymond served as senior counsel at a multinational pharmaceutical manufacturer, where he managed a broad litigation portfolio encompassing intellectual property, commercial, antitrust, employment, and product liability matters. He also led internal investigations and advised on regulatory compliance issues related to the manufacture, distribution, and commercialization of pharmaceutical products. Earlier, he was in house counsel to a global e-commerce, technology, and health care conglomerate, where he advised on FDA and FTC regulations, state and federal privacy laws, fraud and abuse statutes, and TCPA and CAN SPAM compliance.
Raymond earned his JD from the George Washington University Law School, where he served on the Federal Circuit Bar Journal and the Moot Court Board. He received his BS, summa cum laude, in health systems management from the University of Baltimore.
viewpoints
Zafirov Update: Eleventh Circuit Sides With Relators on Appointments Clause, But Article II Challenges Remain
September 3, 2026 | Blog | By Grady Campion, Karen Lovitch , Kevin McGinty, Raymond Vanderhyden
On September 1, 2026, the Eleventh Circuit issued its long-awaited decision in United States ex rel. Zafirov v. Florida Medical Associates, vacating the district court’s ruling that the False Claims Act’s (FCA) qui tam provisions violate the Appointments Clause of Article II. The court found that FCA relators are not “Officers of the United States” because they do not occupy a “continuing position established by law,” and therefore are not subject to the Appointments Clause’s requirements. The Eleventh Circuit’s decision is in line with decisions from other circuits rejecting similar Appointments Clause challenges, but it is the first to do so since Justice Thomas’s dissent in United States ex rel. Polansky v. Executive Health Resources.
Cooperation, Compliance, and Consequences: Inside DOJ's $46 Million Veloxis Settlement
August 26, 2026 | Blog | By Karen Lovitch , Raymond Vanderhyden
The Department of Justice’s recent resolution with Veloxis Pharmaceuticals sends a clear signal: pharmaceutical companies’ relationships with health care professionals remain under close scrutiny. Veloxis Pharmaceuticals Inc., a North Carolina-based drug manufacturer, agreed to pay more than $46 million to resolve criminal and civil allegations arising from a purported years-long kickback scheme involving its kidney transplant drug, Envarsus. The resolution included a deferred prosecution agreement (DPA), a civil False Claims Act (FCA) settlement, and the largest recovery on record under the federal Open Payments Program (Sunshine Act), which underscores the government’s continuing focus on pharmaceutical manufacturers’ relationships with health care professionals (HCPs) and its willingness to pursue both criminal and civil remedies when it considers those relationships to have crossed the line.
The Texas Mini-TCPA’s Exemptions Aren’t Just Theoretical — Sutton Proves It
July 1, 2026 | Article | By Esteban Morales, Raymond Vanderhyden
Texas mini-TCPA update: Sutton v. Senior Life confirms insurance exemption and highlights key Chapter 302 carve-outs for registration claims.
Telephone and Texting Compliance News — June 2026
July 1, 2026 | Article | By Esteban Morales, Danielle Frappier, Jonathan P. Garvin, Raymond Vanderhyden
June 2026 Telephone & Texting Compliance News: FCC KYC, KYUP, STIR/SHAKEN and numbering reforms, plus Texas mini-TCPA Sutton exemption ruling.
DOJ’s 2026 Health Care Fraud Takedown Signals Heightened Medicaid Scrutiny and Data-Driven Enforcement
June 26, 2026 | Blog | By Karen Lovitch , Lauren Moldawer, Raymond Vanderhyden
The annual National Health Care Fraud Takedown, announced by the Department of Justice (DOJ) on June 23, 2026 (the “2026 Takedown”), reinforces several enforcement priorities—opioid diversion, wound care fraud, and kickback schemes—while signaling a sharper focus on Medicaid fraud and the government’s expanding use of advanced data analytics.
FDA in Flux — May 2026 Newsletter
May 19, 2026 | Article | By Joanne Hawana , Benjamin Zegarelli, Raymond Vanderhyden
The May 2026 edition of FDA in Flux highlights significant developments shaping the regulatory landscape for medical, life sciences, and consumer product sectors.
Recent Insights
Cooperation, Compliance, and Consequences: Inside DOJ's $46 Million Veloxis Settlement
August 26, 2026| Blog
